Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 887 participants.

Also called NCT02554890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 887 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02554890
Other papers using this trial's data
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists Journal of the American College of Cardiology, 2020-09-01 DOI, PubMed 32854838
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial JACC. Heart failure, 2020-10 DOI, PubMed 32919915
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial JACC. Heart failure, 2020-10 DOI, PubMed 32800511, PMC7541586 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial JAMA cardiology, 2020-02-01 DOI, PubMed 31825471, PMC6990764 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02554890. Randomized; quadruple masking; primary purpose supportive care. Start 2016-04-29 (actual); primary completion 2018-06-29 (actual). Results posted on 2019-09-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
Acronym
PIONEER-HF
Condition
Acute Heart Failure
Intervention (Drug)
sacubitril/valsartan (LCZ696)
Intervention (Drug)
Enalapril
Intervention (Drug)
sacubitril/valsartan (LCZ696) matching placebo
Intervention (Drug)
enalapril matching placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02554890
Content hash
492357b6362b7a9ebee07605eb471f59624936d381eda932c5ff1cc58282b20f